Download PDF
J Reconstr Microsurg 2004; 20(3): 241-252
DOI: 10.1055/s-2004-823112
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Diabetic Neuropathy: Pathogenesis and Treatment. A Review

Maria Siemionow1 , Yavuz Demir1
  • 1Department of Plastic Surgery, The Cleveland Clinic Foundation, Cleveland, OH
Further Information

Publication History

Accepted: 1 December 2003

Publication Date:
16 April 2004 (online)

    Permissions and Reprints

Neuropathy is a common and devastating complication of diabetes that contributes to mortality in most cases. Multiple factors are thought to play a major role in the pathogenesis of diabetic neuropathy, including alterations in the endoneural metabolism, defective neurotrophic factors, reduced nerve blood supply, and immune mechanisms. Studies of endoneural metabolism and nerve blood-flow alterations have focused on oxidative stress, the polyol pathway, advanced glycation, protein kinase C, and impaired essential fatty acid metabolism. Although many experimental and clinical studies have been performed to determine the most optimal strategy for preventing and treating diabetic neuropathy, tight glycemic control is the mainstay of therapy. In this article, the proposed pathophysiologic mechanisms and therapeutic approaches in diabetic neuropathy are reviewed and discussed with the relevant literature.

KEYWORDS

Diabetic neuropathy - pathogenesis - treatment - decompression

REFERENCES

  • 1 Sima A A, Thomas P K, Ishii D, Vinik A. Diabetic neuropathies.  Diabetologia. 1997;  40 B74-B77
    CrossrefPubMedGoogle Scholar
  • 2 Greene D A, Stevens M J, Feldman E L. Diabetic neuropathy: scope of syndrome.  Am J Med. 1999;  107 2S-8S
    PubMedGoogle Scholar
  • 3 The DCCT Research Group . Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetes control and complications trial.  Diabetes. 1988;  37 476-481
    PubMedGoogle Scholar
  • 4 Sangiorgio L, Iemmolo R, Le Moli R et al.. Diabetic neuropathy: prevalence, concordance between clinical and electrophysiological testing and impact of risk factors.  Panminerva Med. 1997;  39 1-5
    PubMedGoogle Scholar
  • 5 Fedele D, Comi G, Coscelli C et al.. A multicentre study on the prevalence of diabetic neuropathy in Italy: Italian diabetic neuropathy group.  Diabetes Care. 1997;  20 836-843
    CrossrefPubMedGoogle Scholar
  • 6 Vaillancourt P D, Langevin H M. Painful peripheral neuropathies.  Med Clin North Am. 1999;  83 627-642
    CrossrefPubMedGoogle Scholar
  • 7 Thomas P K. Classification, differential diagnosis and staging of diabetic peripheral neuropathy.  Diabetes. 1997;  46(suppl 2) S54-S57
    Google Scholar
  • 8 Anand P, Terenghi G, Warner G et al.. The role of endogenous nerve growth factor in human diabetic neuropathy.  Nat Med. 1996;  2 703-707
    PubMedGoogle Scholar
  • 9 Cameron N E, Eaton S E, Cotter M A, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.  Diabetologia. 2001;  44 1973-1988
    CrossrefPubMedGoogle Scholar
  • 10 Diabetes Control and Complication Trial (DCCT) Research Group . The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus.  N Eng J Med. 1993;  329 977-986
    Google Scholar
  • 11 Vinik A I. Diabetic neuropathy: pathogenesis and therapy.  Am J Med. 1999;  107 (2B) 17S-26S
    CrossrefPubMedGoogle Scholar
  • 12 Van Dam P S. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives.  Diabetes Met Res Rev. 2002;  18 176-184
    PubMedGoogle Scholar
  • 13 Greene D A, Lattimer S A, Sima A A. Perspectives in diabetes: are disturbances of sorbitol phosphoinositide and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?.  Diabetes. 1988;  37 688-693
    PubMedGoogle Scholar
  • 14 Cameron N E, Cotter M A. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.  Diabetes Res Clin Prac. 1999;  45 137-146
    CrossrefPubMedGoogle Scholar
  • 15 Ward K K, Low P A, Schmelzer J D, Zochodne D W. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats.  Brain. 1989;  112 197-208
    PubMedGoogle Scholar
  • 16 Low P A, Nickander K K, Tritschler H J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy.  Diabetes. 1997;  46(suppl. 2) S38-S42
    CrossrefPubMedGoogle Scholar
  • 17 Wolff S P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications.  Br Med Bull. 1993;  49 642-652
    CrossrefPubMedGoogle Scholar
  • 18 Blakytyn R, Harding J J. Glycation (non-enzymatic glycosylation) inactivates glutathion reductase.  Biochem J. 1992;  288 303-307
    PubMedGoogle Scholar
  • 19 Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications.  Nutrition. 2001;  17 888-895
    CrossrefPubMedGoogle Scholar
  • 20 Lindner V, Collins T. Expression of NF-kappa B and I kappa B-alpha by aortic endothelium in an arterial injury model.  Am J Pathol. 1996;  148 427-438
    PubMedGoogle Scholar
  • 21 Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals.  J Membr Biol. 1986;  89 1-8
    PubMedGoogle Scholar
  • 22 Takagi Y, Kashiwagi A, Tanaka Y et al.. Significance of fructose-induced protein oxidation and formation of advanced glycation end product.  J Diabetes Complications. 1995;  9 87-91
    CrossrefPubMedGoogle Scholar
  • 23 Greene D A, Lattimer S A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation.  J Clin Invest. 1983;  72 1058-1063
    PubMedGoogle Scholar
  • 24 Yorek M A, Dunlap J A, Stefani M R. Restoration of Na+-K+ pump activity and resting membrane potential by myo-inositol supplementation in neuroblastoma cells chronically exposed to glucose or galactose.  Diabetes. 1991;  40 240-248
    PubMedGoogle Scholar
  • 25 Cameron N E, Cotter M A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy.  Diabetes. 1997;  46(suppl 2) S31-S37
    PubMedGoogle Scholar
  • 26 Pop-Busui R, Marinescu V, Van Huysen C et al.. Dissection of metabolic, vascular and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.  Diabetes. 2002;  51 2619-2628
    PubMedGoogle Scholar
  • 27 Yasuda H, Dyck P J. Abnormalities of endoneural microvessels and sural nerve pathology in diabetic neuropathy.  Neurology. 1987;  37 20-28
    PubMedGoogle Scholar
  • 28 Giannini C, Dyck P J. Ultrastructural morphometric abnormalities of sural nerve endoneural microvessels in diabetes mellitus.  Ann Neurol. 1994;  36 408-415
    CrossrefPubMedGoogle Scholar
  • 29 Tesfaye S, Malik R, Ward J D. Vascular factors in diabetic neuropathy.  Diabetologia. 1994;  37 847-854
    CrossrefPubMedGoogle Scholar
  • 30 Tuck R R, Schmelzer J D, Low P A. Endoneural blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy.  Brain. 1984;  107 935-950
    PubMedGoogle Scholar
  • 31 Stevens E J, Carrington A L, Tomlinson D R. Nerve ischemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models.  Diabetologia. 1994;  37 43-48
    PubMedGoogle Scholar
  • 32 Tesfaye S, Harris N, Jakubowski J J et al.. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography.  Diabetologia. 1993;  36 1266-1274
    CrossrefPubMedGoogle Scholar
  • 33 Young M J, Veves A, Walker M G, Boulton A J. Correlation between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy?.  Diabetologia. 1992;  35 1146-1150
    CrossrefPubMedGoogle Scholar
  • 34 Kilo S, Berghoff M, Hilz M, Freeman R. Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy.  Neurology. 2002;  54 1246-1252
    PubMedGoogle Scholar
  • 35 Kihara M, Low P A. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy.  Exp Neurol. 1995;  132 180-185
    CrossrefPubMedGoogle Scholar
  • 36 Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.  J Clin Invest. 1991;  87 432-438
    CrossrefPubMedGoogle Scholar
  • 37 Apfel S C. Neurotrophic factors in the therapy of diabetic neuropathy.  Am J Med. 1999;  107 (2B) 34S-42S
    PubMedGoogle Scholar
  • 38 Hellweg R, Raivich G, Hartung H D et al.. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy.  Exp Neurol. 1994;  130 24-30
    CrossrefPubMedGoogle Scholar
  • 39 Brewster W J, Fernyhough P, Diemel L T et al.. Diabetic neuropathy, nerve growth factor and other neurotrophic factors.  Trends Neurosci. 1994;  17 321-325
    CrossrefPubMedGoogle Scholar
  • 40 Tomlinson D R, Fernyhough P, Diemel L T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors.  Diabetes. 1997;  46(Suppl) S43-S49
    PubMedGoogle Scholar
  • 41 Wuarin L, Guertin D M, Ishii D N. Early reduction in insulin-like growth factor gene expression in diabetic nerve.  Exp Neurol. 1994;  130 106-114
    CrossrefPubMedGoogle Scholar
  • 42 Tan K, Baxter R C. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age.  J Clin Endocrinol Metab. 1986;  63 651-655
    PubMedGoogle Scholar
  • 43 Hafer-Macko C E, Ivey F M, Gyure K A et al.. Thrombomodulin deficiency in human diabetic nerve microvasculature.  Diabetes. 2002;  51 1957-1963
    CrossrefPubMedGoogle Scholar
  • 44 Esposito C, Gerlach H, Brett J et al.. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.  J Exp Med. 1989;  170 1387-1407
    CrossrefPubMedGoogle Scholar
  • 45 Ferreira L D, Huey P U, Pilford B E et al.. Sciatic nerve lipoprotein lipase is reduced in streptozotocin-induced diabetes and corrected by insulin.  Endocrinology. 2002;  143 1213-1217
    CrossrefPubMedGoogle Scholar
  • 46 Huey P U, Marcell T, Owens G C et al.. Lipoprotein lipase is expressed in cultured Schwann cells and functions in lipid synthesis and utilization.  J Lipid Res. 1998;  39 2135-2142
    PubMedGoogle Scholar
  • 47 Sharma K R, Cross J, Ayyar D R et al.. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy.  Arch Neurol. 2002;  59 751-757
    CrossrefPubMedGoogle Scholar
  • 48 Said G, Goulon Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy.  Ann Neurol. 1994;  35 559-569
    CrossrefPubMedGoogle Scholar
  • 49 Cocito D, Ciaramitaro P, Isoardo G et al.. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.  J Neurol. 2002;  249 719-722
    PubMedGoogle Scholar
  • 50 Krendel D A, Zacharias A, Younger D S. Autoimmune diabetic neuropathy.  Neurol Clin. 1997;  15 959-971
    CrossrefPubMedGoogle Scholar
  • 51 Younger D S, Rosoklija G, Hays A P et al.. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies.  Muscle Nerve. 1996;  19 722-727
    PubMedGoogle Scholar
  • 52 Kelkar P, Masood M, Parry G J. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy).  Neurology. 2000;  55 83-88
    PubMedGoogle Scholar
  • 53 Vinik A I, Leichter S B, Pittenger G L et al.. Phospholipid and glutamic acid decarboxylase antibodies in diabetic polyneuropathy.  Diabetes Care. 1995;  18 1225-1232
    CrossrefPubMedGoogle Scholar
  • 54 Bravenboer B, Kappelle A C, Hamers F P et al.. Potential use of glutathion for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat.  Diabetologia. 1992;  35 813-817
    CrossrefPubMedGoogle Scholar
  • 55 Van Dam P S, Van Asbeck B S, Van Oirschot J F et al.. Glutathion and α lipoate in diabetic rats: nerve function, blood flow and oxidative state.  Eur J Clin Invest. 2001;  31 417-424
    CrossrefPubMedGoogle Scholar
  • 56 Ueno Y, Kizaki M, Nakagiri R et al.. Dietary glutathion protects rats from diabetic nephropathy and neuropathy.  J Nutr. 2002;  132 897-900
    PubMedGoogle Scholar
  • 57 Wada H, Shintani D, Ohlrogge J. Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production.  Proc Natl Acad Sci USA. 1997;  94 1591-1596
    CrossrefPubMedGoogle Scholar
  • 58 Ou P, Tritschler H J, Wolff S P. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?.  Biochem Pharmacol. 1995;  50 123-126
    CrossrefPubMedGoogle Scholar
  • 59 Stevens M J, Obrosova I, Cao X et al.. Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy.  Diabetes. 2000;  49 1006-1015
    CrossrefPubMedGoogle Scholar
  • 60 Cameron N E, Cotter M A, Horrobin D H, Tritschler H J. Effects of α lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids.  Diabetologia. 1998;  41 390-399
    CrossrefPubMedGoogle Scholar
  • 61 Hounsom L, Horrobin D F, Tritschler H et al.. A lipoic acid-gamma linoleic acid conjugate is effective against multiple indices of experimental diabetic neuropathy.  Diabetologia. 1998;  41 839-843
    CrossrefPubMedGoogle Scholar
  • 62 Biessels G J, Smale S, Duis S E et al.. The effects of gamma-linoleic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats.  J Neurol Sci. 2001;  182 99-106
    CrossrefPubMedGoogle Scholar
  • 63 Ziegler D, Hanefeld M, Ruhnau K J et al.. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study).  Diabetologia. 1995;  38 1425-1433
    CrossrefPubMedGoogle Scholar
  • 64 Ziegler D, Schatz H, Conrad F et al.. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicentre trial (DEKAN Study).  Diabetes Care. 1997;  20 369-373
    PubMedGoogle Scholar
  • 65 Ziegler D, Hanefeld M, Ruhnau K J et al.. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 7-month multicentre randomized controlled trial (ALADIN III Study). ALADIN III Study Group Alpha-Lipoic Acid in Diabetic Neuropathy.  Diabetes Care. 1999;  22 1296-1301
    PubMedGoogle Scholar
  • 66 Kunt T, Forst T, Wilhelm A et al.. Alpha-lipoic acid reduces expression of vascular adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products.  Clin Sci (Lond). 1999;  96 75-82
    PubMedGoogle Scholar
  • 67 Cotter M A, Love A, Watt M J et al.. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats.  Diabetologia. 1995;  38 1285-1294
    PubMedGoogle Scholar
  • 68 Tütüncü N B, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study.  Diabetes Care. 1998;  21 1915-1918
    PubMedGoogle Scholar
  • 69 Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes.  Am J Clin Nutr. 2001;  73 1052-1057
    PubMedGoogle Scholar
  • 70 Cameron N E, Cotter M A. Neurovascular dysfunction in diabetic rats: potential contribution of autooxidation and free radicals examined using transition metal chelating agents.  J Clin Invest. 1995;  96 1159-1163
    CrossrefPubMedGoogle Scholar
  • 71 Keegan A, Cotter M A, Cameron N E. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats.  Free Radic Biol Med. 1999;  27 536-543
    CrossrefPubMedGoogle Scholar
  • 72 Cameron N E, Cotter M A. Effects of an extracellular metal chelator on neurovascular function in diabetic rats.  Diabetologia. 2001;  44 621-628
    CrossrefPubMedGoogle Scholar
  • 73 Pop-Busui R, Sullivan K A, Van Huysen C et al.. Depletion of taurine in experimental diabetic neuropathy: Implications for nerve metabolic, vascular and functional deficits.  Exp Neurol. 2001;  168 259-272
    CrossrefPubMedGoogle Scholar
  • 74 Obrosova I G, Fathallah L, Stevens M J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy.  Exp Neurol. 2001;  172 211-219
    CrossrefPubMedGoogle Scholar
  • 75 Bril V. Status of current clinical trials in diabetic neuropathy.  Can J Neurol Sci. 2001;  28 191-198
    PubMedGoogle Scholar
  • 76 Greene D A, Arezzo J C, Brown M B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.  Neurology. 1999;  53 580-591
    CrossrefPubMedGoogle Scholar
  • 77 Daniele E, Coco M P. Tolrestat in the therapy of diabetic peripheral neuropathy. Is this drug really useful?.  Clin Ther. 1995;  146 793-799
    PubMedGoogle Scholar
  • 78 Obrosova I G, Van Huysen C, Fathallah L et al.. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism and oxidative defense.  FASEB J. 2002;  16 123-125
    CrossrefPubMedGoogle Scholar
  • 79 Handelsman D, Turtle J. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.  Diabetes. 1981;  30 459-464
    PubMedGoogle Scholar
  • 80 Christensen J, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.  Acta Neurol Scand. 1985;  71 164-167
    PubMedGoogle Scholar
  • 81 Uchida K, Kigoshi T, Nakano S et al.. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.  Clin Ther. 1995;  17 460-466
    CrossrefPubMedGoogle Scholar
  • 82 Asano T, Saito Y, Kawakami M, Yamada N. (Fidarestat Clinical Pharmacology Study Group) . Fidarestat (SNK-60), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.  J Diabetes Complications. 2002;  16 133-138
    CrossrefPubMedGoogle Scholar
  • 83 Cameron N E, Cotter M A, Dines K C et al.. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.  Diabetologia. 1997;  37 651-663
    PubMedGoogle Scholar
  • 84 Koya D, King G L. Protein kinase C activation and the development of diabetic complications.  Diabetes. 1998;  47 859-866
    CrossrefPubMedGoogle Scholar
  • 85 Nakamura J, Kato K, Hamada Y et al.. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.  Diabetes. 1999;  48 2090-2095
    CrossrefPubMedGoogle Scholar
  • 86 Cotter M A, Jack A M, Cameron N E. Effects of protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes.  Clin Sci (Lond). 2002;  103 311-321
    PubMedGoogle Scholar
  • 87 Keen H, Payan J, Allawi J et al.. Treatment of diabetic neuropathy with γ-linoleic acid.  Diabetes Care. 1993;  16 8-15
    PubMedGoogle Scholar
  • 88 Cotter M A, Cameron N E. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats.  Prostaglandins Leukot Essent Fatty Acids. 1997;  56 337-343
    CrossrefPubMedGoogle Scholar
  • 89 Petty B G, Cornblath D R, Adornato B T et al.. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.  Ann Neurol. 1994;  36 244-246
    CrossrefPubMedGoogle Scholar
  • 90 Apfel S C, Kessler J A, Adornato B T et al.. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy.  Neurology. 1998;  51 695-702
    CrossrefPubMedGoogle Scholar
  • 91 Apfel S C, Schwartz S, Adornato B T et al.. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial.  JAMA. 2000;  284 2215-2221
    CrossrefPubMedGoogle Scholar
  • 92 Goss R J, Goins F W, Lacomis D et al.. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse.  Diabetes. 2002;  51 2227-2232
    PubMedGoogle Scholar
  • 93 Apfel S C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right and what does the future hold ?.  Int Rev Neurobiol. 2002;  50 393-413
    PubMedGoogle Scholar
  • 94 Zhuang H X, Snyder C K, Pu S F, Ishii D N. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats.  Exp Neurol. 1996;  140 198-205
    CrossrefPubMedGoogle Scholar
  • 95 Wang C, Li Y, Wible B et al.. Effects of insulin and insulin like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells.  Brain Res Mol Brain Res. 1992;  13 289-300
    PubMedGoogle Scholar
  • 96 Calcutt N A, Campana W M, Eskeland N L et al.. Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats.  J Neuropathol Exp Neurol. 1999;  58 628-636
    PubMedGoogle Scholar
  • 97 Krendel D A, Costigan D A, Hopkins L C. Successful treatment of neuropathies in patients with diabetic mellitus.  Arch Neurol. 1995;  52 1053-1061
    PubMedGoogle Scholar
  • 98 Ogawa T, Taguchi T, Tanaka Y et al.. Intravenous immunoglobulin therapy for diabetic amyotrophy.  Intern Med. 2001;  40 349-52
    PubMedGoogle Scholar
  • 99 Awada A, Dehoux E, al Jumah M, al Ayafi H. Rapidly evolving diabetic mononeuritis multiplex. Favorable outcome after immunosuppressive treatment.  Rev Neurol (Paris). 2001;  157 1427-1429
    PubMedGoogle Scholar
  • 100 Yagihashi S, Kamijo M, Baba M et al.. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats.  Diabetes. 1992;  Jan;41 47-52
    PubMedGoogle Scholar
  • 101 Cameron N E, Cotter M A, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats.  Diabetologia. 1992;  35 946-950
    CrossrefPubMedGoogle Scholar
  • 102 Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats.  Microvasc Res. 1997;  53 105-112
    PubMedGoogle Scholar
  • 103 Wada R, Sugo M, Nakano M, Yagihashi S. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+,K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats.  Diabetologia. 1999;  42 743-747
    CrossrefPubMedGoogle Scholar
  • 104 Zhang W, Slusher B, Murakawa Y et al.. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.  J Neurol Science. 2002;  194 21-28
    PubMedGoogle Scholar
  • 105 Butcher S P, Bullock R, Graham D I, McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion.  Stroke. 1990;  21 1727-1733
    PubMedGoogle Scholar
  • 106 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen K F et al.. Effect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy: the Oslo study.  Br Med J. 1986;  293 1195-1199
    CrossrefPubMedGoogle Scholar
  • 107 Dahl-Jorgensen K. Near-normoglycemia and late diabetic complications: the Oslo study.  Acta Endocrinol. 1987;  115(suppl) 1-38
    PubMedGoogle Scholar
  • 108 DCCT . The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).  Diabetologia. 1998;  41 416-423
    CrossrefPubMedGoogle Scholar
  • 109 Parry G J. Management of diabetic neuropathy.  Am J Med. 1999;  107 (2B) 27S-33S
    PubMedGoogle Scholar
  • 110 Potter C G, Sharma A K, Farber M O, Peterson R G. Hypoglycemic neuropathy in experimental diabetes.  J Neurol Sci. 1988;  88 293-301
    CrossrefPubMedGoogle Scholar
  • 111 Ohshima J, Nukada H. Hypoglycemic neuropathy: microvascular changes due to recurrent hypoglycemic episodes in rat sciatic nerve.  Brain Res. 2002;  947 84-89
    CrossrefPubMedGoogle Scholar
  • 112 Orloff M J, Macedo A, Greenleaf G E. Effect of pancreas transplantation on diabetic somatic neuropathy.  Surgery. 1988;  104 437-444
    PubMedGoogle Scholar
  • 113 Müller-Felber W, Landgraf L, Scheuer R et al.. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation.  Diabetes. 1993;  42 1482-1486
    PubMedGoogle Scholar
  • 114 Martinenghi S, Comi G, Galardi G et al.. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycemic control provided by the pancreas.  Diabetologia. 1997;  40 1110-1112
    CrossrefPubMedGoogle Scholar
  • 115 Navarro X, Sutherland D E, Kennedy W R. Long-term effects of pancreas transplantation on diabetic neuropathy.  Ann Neurol. 1997;  42 727-736
    CrossrefPubMedGoogle Scholar
  • 116 Hopt U T, Drognitz O. Pancreas organ transplantation. Short and long-term results in terms of diabetes control.  Langenbeck's Arch Surg. 2000;  385 379-389
    PubMedGoogle Scholar
  • 117 Landgraf R. Impact of pancreas transplantation on diabetic secondary complications and quality of life.  Diabetologia. 1996;  39 1415-1424
    CrossrefPubMedGoogle Scholar
  • 118 Vàrkonyi T T, Farkas G, Fülöp Z et al.. Beneficial effects of fetal islet grafting on development of late diabetic complications.  Transplant Proc. 1998;  30 330-331
    CrossrefPubMedGoogle Scholar
  • 119 Kale B, Yuksel F, Celikoz B et al.. Effect of various nerve decompression procedures on the functions of distal limbs in streptozotocin-induced diabetic rats: further optimism in diabetic neuropathy.  Plast Reconstr Surg. 2003;  111 2265-2272
    CrossrefPubMedGoogle Scholar
  • 120 Dellon A L. Treatment of symptomatic diabetic neuropathy by surgical decompression of multiple peripheral nerves.  Plast Reconstr Surg. 1992;  89 689-697
    PubMedGoogle Scholar
  • 121 Dellon A L. Preventing foot ulceration and amputation by decompressing peripheral nerves in patients with diabetic neuropathy.  Ostomy Wound Management. 2002;  9 36-45
    PubMedGoogle Scholar
  • 122 Aszmann O C, Kress K M, Dellon A M. Results of decompression of peripheral nerves in diabetics: a prospective, blinded study.  Plast Reconstr Surg. 2000;  106 816-822
    CrossrefPubMedGoogle Scholar
  • 123 Dellon A L, MacKinnon S E, Seiler W A. Susceptibility of the diabetic nerve to chronic compression.  Ann Plast Surg. 1988;  20 117-119
    CrossrefPubMedGoogle Scholar
  • 124 Dellon A L, Dellon E S, Seiler W A. Effect of tarsal tunnel decompression in streptozotocin-induced diabetic rats.  Microsurgery. 1994;  15 265-268
    CrossrefPubMedGoogle Scholar
  • 125 Tambwekar S R. Extended neurolysis of the posterior tibial nerve to improve sensation in diabetic feet.  Plast Reconstr Surg. 2001;  108 1452-3
    CrossrefPubMedGoogle Scholar
  • 126 Caffee H H. Treatment of diabetic neuropathy by decompression of the posterior tibial nerve.  Plast Reconstr Surg. 2000;  106 813-815
    PubMedGoogle Scholar

Maria SiemionowM.D. Ph.D. 

The Cleveland Clinic Foundation

9500 Euclid Avenue, A60

Cleveland, OH 44195

      >